University of Chicago Medicine Comprehensive Cancer Center | Strategic Alliance Partners

October 05, 2016

​Jonas de Souza, MD, assistant professor of medicine, University of Chicago, discusses the approval of pembrolizumab for relapsed head and neck cancer patients who are platinum-refractory

September 15, 2016

Stanley Liauw, MD, associate professor at the University of Chicago Medicine, discusses the advancements in radiation therapy (RT) over the last several years, and how he has seen the treatment affect his patients.

August 16, 2016

Russell Szmulewitz, MD, discusses the unknown optimal use of radium-223 dichloride (Xofigo), the appropriate time to administer it, and the associated challenges with the agent for the treatment of patients with metastatic castration-resistant prostate cancer.

August 11, 2016

Akash Patnaik, MD, PhD, assistant professor of Medicine at the University of Chicago Medicine, discusses the challenges with sequencing available agents for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

August 11, 2016

Gary D. Steinberg, MD, discusses the impact of atezolizumab (Tecentriq) on the treatment landscape of bladder cancer, the resistance to finding effective therapies for the disease, and what potential role immunotherapy may have in the field going forward.

August 11, 2016

Randy F. Sweis, MD, covers the immunotherapy advancements in prostate cancer, renal cell carcinoma, and bladder cancer, and what refinement lies ahead in each of these areas.

August 02, 2016

Russell Szmulewitz, MD, discusses optimal treatment strategies for patients with metastatic castration-resistant prostate cancer and highlights emerging therapies in the therapeutic landscape.

July 21, 2016

Scott Eggener, MD, discusses the implications of the Prostate, Lung, Colorectal, and Ovary trial update, and shares his views on PSA-based screening and how to appropriately use it for patients with early-stage prostate cancer.

July 19, 2016

Andrzej Jakubowiak, MD, PhD, professor of Medicine, director, Myeloma Program, University of Chicago Medicine, discusses the likelihood of finding a cure for patients with multiple myeloma.

July 14, 2016

Peter O'Donnell, MD, discusses the encouraging IMvigor 210 results, the impact of atezolizumab (Tecentriq) in the treatment landscape, and the role of immunotherapy in metastatic urothelial carcinoma.

July 12, 2016

Walter M. Stadler, MD, discusses emerging therapies, the most overriding challenges in a specific subset of patients, and understanding the evolving role of chemotherapy in metastatic castration-sensitive prostate cancer.

May 25, 2016

Russell Szmulewitz, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the optimal use of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer.

May 19, 2016

Gary D. Steinberg, MD, Bruce and Beth White Family Professor, professor of Surgery, director of Urologic Oncology, University of Chicago Medicine, discusses the FDA approval of atezolizumab (Tecentriq) as a treatment for patients with with locally advanced or metastatic urothelial carcinoma (mUC) whose disease progressed during or after platinum-based chemotherapy, or within 12 months of receiving platinum-containing chemotherapy, either before or after surgery.

April 07, 2016

PD-1/PD-L1 should be the backbone of melanoma treatment for many patients, says Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine.

March 28, 2016

Tanguy Seiwert, MD, discusses the impact of the CheckMate-141 trial in head and neck cancer, the importance of establishing an effective biomarker, and the significance a manageable toxicity profile may have on patients with poor performance status.

January 05, 2016

Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses what the future holds for combination therapies for patients with melanoma.

December 29, 2015

Thomas F. Gajewski, MD, PhD, discusses how the field of immune checkpoints is expanding beyond PD-1 and CTLA-4.

September 17, 2015

Jason J. Luke, MD, assistant professor of Medicine, University of Chicago Medicine, discusses combination approaches that are on the horizon for the treatment of patients with melanoma.

August 28, 2015

Immune checkpoint inhibitors can be of significant value in combatting recurrent and metastatic triple negative breast cancer, Rita Nanda, MD, told physicians at the recent 14th Annual International Congress on the Future of Breast Cancer.

July 24, 2015

Tanguy Y. Seiwert, MD, discusses the significance of the expansion results of KEYNOTE-012 for advanced squamous cell carcinoma of the head and neck.